Japan Lifeline Co., Ltd. Provides Earnings Guidance for the Six Months Ending September 30, 2021 and Full Year of Ending March 31, 2022
August 04, 2021 at 02:10 am EDT
Share
Japan Lifeline Co., Ltd. provided earnings guidance for the six months ending September 30, 2021 and full year of ending March 31, 2022. For the six months, the company expects net sales of JPY 25,144 million, operating profit of JPY 4,398 million, profit attributable to owners of parent of JPY 3,255 million and earnings per share of JPY 40.49.
For the year ending March 31, 2022, the company expects net sales of JPY 52,979 million, operating profit of JPY 10,625 million, profit attributable to owners of parent of JPY 7,567 million and earnings per share of JPY 94.11.
Japan Lifeline Co., Ltd. is a Japan-based company mainly engaged in the import, manufacture and sale of cardiac circulators and other medical devices. The Company is mainly engaged in the production of rhythm devices, electrophysiological (EP) and ablations, surgical products and intervention products. The rhythm devices include cardiac pacemakers, implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy defibrillator (CRT-D) and other rhythm devices. The EP and ablations include EP catheters for cardiac arrhythmia examination, ablation catheters for arrhythmia treatment and other EP and ablations. The surgical products include prosthetic heart valves and annuloplasty rings for heart disease surgical treatment, vascular grafts, open stent grafts and stent grafts for aortic disease treatment, as well as other surgical products. The intervention products include balloon catheters, guide wires, penetration catheters and other intervention products.
JAPAN LIFELINE CO., LTD. 
